表观遗传年龄加速与美国老年人听力功能的关联
该研究基于健康与退休研究2016年样本中1755名50岁及以上成年人的数据,分析五种表观遗传时钟与听力功能的关系。结果显示表型年龄加速、GrimAA和DunedinPoAm与较低听力测试得分显著相关,GrimAA与听力损失风险升高相关,且这些关联在女性中更显著。
要点
- 表观遗传年龄加速与老年人听力功能下降相关
- GrimAA与听力损失风险升高相关,尤其在女性中
- 性别差异在表观遗传与听力关联中需重视
核心结论
- 表观遗传年龄加速可能是老年人听力损失的生物标志物。
- 表观遗传年龄加速与听力功能的关联存在性别差异,女性中更显著。
研究设计与样本
- 研究分析了健康与退休研究2016年样本中1755名50岁及以上成年人的数据。
- 采用多变量回归模型评估五种表观遗传时钟与平均听力测试得分(线性)及听力损失(逻辑)的关联。
主要发现
- 参与者平均实际年龄为68.4(SD=9.4)岁,平均表观遗传年龄从HannumAge的53.9(SD=8.9)岁到GrimAge的67.1(SD=8.6)岁不等。
- 58.4%的参与者存在听力损失,平均听力测试得分为4.6(1.4)。
- 表型年龄加速、GrimAA和DunedinPoAm与较低听力测试得分显著相关,β[95%CI]分别为-0.081[-0.15至-0.01]、-0.150[-0.22至-0.08]、-0.089[-0.16至-0.02]。
- 这些关联在女性中保持显著,而在男性中仅GrimAA仍显著。
- GrimAA与听力损失风险升高相关(OR[95%CI]=1.23[1.05至1.44]),且在女性中显著(1.47[1.18至1.83]),男性中不显著。
临床怎么用
- 表观遗传年龄加速可作为识别老年人听力损失风险的潜在生物标志物。
- 临床评估听力损失时需考虑性别差异,尤其对女性应关注表观遗传年龄加速的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hearing loss is a prevalent condition in older adults. Epigenetic age acceleration has emerged as a potential biomarker for age-related diseases; however, there is limited evidence of the link between epigenetic age acceleration and hearing loss in older adults or how it varies by sex. This study is to investigate (1) the association between epigenetic age acceleration and hearing function and (2) sex differences in this association. DESIGN: Data from the Health and Retirement Study, a large, nationally representative sample of adults aged 50 yrs and older, were analyzed. The study included 1755 adults from the 2016 sample with epigenetic data. Epigenetic age acceleration included five epigenetic clocks: Horvath's age acceleration (HorvathAA), Hannum's age acceleration (HannumAA), phenotypic age acceleration (PhenoAA), GrimAge acceleration (GrimAA), and methylation-based pace of aging estimate (DunedinPoAm). Multivariable regression models assessed the association between epigenetic age acceleration and mean hearing test score (linear) and hearing loss (logistic). RESULTS: The mean chronological age of 68.4 (SD = 9.4) was higher than the mean epigenetic age ranging from 53.9 (SD = 8.9) for HannumAge to 67.1 (SD = 8.6) for GrimAge. Overall, 58.4% of participants had hearing loss, with a mean hearing test score of 4.6 (1.4). Phenotypic age acceleration, GrimAA, and methylation-based pace of aging estimate were significantly associated with lower hearing test scores ( β [95% confidence interval {CI}] = -0.081 [-0.15 to -0.01]; -0.150 [-0.22 to -0.08]; -0.089 [-0.16 to -0.02], respectively). These associations remained significant in females, while only GrimAA was still significant in males. GrimAA was associated with higher odds of hearing loss (odds ratio [95% CI] =1.23 [1.05 to 1.44]), and remained significant in females (1.47 [1.18 to 1.83]), but not in males. CONCLUSIONS: This study highlights the potential of epigenetic age acceleration as a biomarker for hearing loss in older adults and underscores the importance of sex differences in aging research. Findings suggest further research is needed to explore epigenetic mechanisms as potential targets for interventions to mitigate hearing loss in older adults, particularly among females.
引用
- West JS, Chen Q, Smith SL, et al. Epigenetic Age Acceleration and Hearing Function in US Older Adults. Ear Hear. 2026. PMID: 41645414. doi:10.1097/AUD.0000000000001797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。